EIKCS 2021: Biomarkers for kidney cancer

Dr Thomas Powles from St Barts Hospital, London spoke about the work looking for tissue-based biomarkers for renal cell carcinoma (RCC) for potential use in the clinic at the European International Kidney Cancer Symposium (EIKC) 2021 Virtual Meeting. To date, the only biomarker that is used is one to predict survival (prognosis) based on the […]

read more

New risk scoring system for metastatic kidney cancer

The treatment options for metastatic renal cell carcinoma (RCC) have changed considerably over the past 10 years with the introduction of immunotherapies, such as nivolumab, ipilimumab and pembrolizumab. However, with the new treatments comes the challenge of selecting the most effective treatment for each individual patient. Clinicians are constantly looking for ways to discover which […]

read more

Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer

A paper published in The Oncologist last month analysed real-world data to further evaluate the effectiveness of first-line sunitinib in patients with metastatic renal cell carcinoma (mRCC) with favourable, intermediate or poor risk disease according to the International mRCC Database Consortium (IMDC) risk criteria. The study included 1769 patients; 318 (18.0%) had favourable risk, 1031 […]

read more

Biomarkers for kidney cancer

This interview from Practice Update with Dr Neeraj Agarwal from the Hunstman Cancer Center, Salt Lake City, Utah, USA discusses current and potential biomarkers for renal cell carcinoma (RCC). The two most common models currently used in the clinic are the Memorial Sloan-Kettering (MSKCC) model and the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model, […]

read more

Predictive biomarkers in metastatic kidney cancer

A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can […]

read more

Overall survival data for kidney cancer patients treated with high dose interleukin-2

A retrospective study recently reported in Journal for Immunotherapy of Cancer looked at the survival of renal cell carcinoma (RCC) patients who were assessed using the International Metastatic RCC Database Consortium (IMDC) for RCC risk and treated with high dose interleukin-2 (IL-2). These patients were entered on the PROCLAIMSM data base. The patients were followed […]

read more

Immunoscore system to predict kidney cancer patient outcomes

A recent study by researchers in China, and published in the Journal of Cancer, assessed the¬†Immunoscore system to determine if it can predict survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The presence of various protein receptors on the cancer cells were analysed. Levels of protein receptors for […]

read more

New prognostic factor for metastatic renal cell carcinoma

A retrospective study has shown that a high systemic immune-inflammation index (SII) score is an independent indicator for poor overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The researchers suggest that the neutrophil and platelet counts in the¬†International Metastatic Renal Cell Carcinoma Database Consortium¬†(IMDC) model to predict […]

read more
Showing all 8 results
  TOP